Clincosm LogoSign in Get a demo

ABC2: Meropenem and Piperacillin Plasma Concentrations During CRRT

Sponsor
Karolinska University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04203784
Collaborator
(none)
135
Enrollment
1
Location
50
Actual Duration (Months)
2.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This observational study reports meropenem and piperacillin plasma concentrations in patients treated with either antibiotic and simultaneous continuous renal replacement therapy (CRRT).

Condition or Disease Intervention/Treatment Phase
  • Other: Plasma concentration measurements

Study Design

Study Type:
Observational
Actual Enrollment :
135 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Meropenem and Piperacillin Plasma Concentrations During CRRT
Actual Study Start Date :
Nov 1, 2012
Actual Primary Completion Date :
Dec 31, 2016
Actual Study Completion Date :
Dec 31, 2016

Arms and Interventions

Arm Intervention/Treatment
Meropenem treated patients

Other: Plasma concentration measurements
Plasma concentration measurements
Piperacillin treated patients

Other: Plasma concentration measurements
Plasma concentration measurements

Outcome Measures

Primary Outcome Measures

  1. Plasma antibiotic concentrations at mid and end of dosing interval [1 week]

    We vill report the measured plasma antibiotic concentrations at the mid and end of the dosing interval.

  2. Plasma antibiotic concentrations at mid and end of dosing interval [1 week]

    The percentage of patients having a concentration above the highest MIC (minimal inhibitory concentration) breakpoint for pathogens considered susceptible for the antibiotic.

  3. Relationships between plasma antibiotic concentrations and CRRT dose. [1 week]

    We will report the correlation between measured plasma concentrations of either antibiotic and the intensity of the CRRT treatment.

  4. Influence of residual diuresis on the measured plasma antibiotic concentrations. [1 week]

    We will report the correlation between measured plasma concentrations of either antibiotic and residual diuresis.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:

  • patients treated in the study ICU and

  • simultaneous CRRT and antibiotic treatment with either meropenem or piperacillin-tazobactam.

Exclusion Criteria:
  • none

Contacts and Locations

Locations

Site City State Country Postal Code
1 Karolinska University Hospital Solna Stockholm Sweden 17176

Sponsors and Collaborators

  • Karolinska University Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Johan Petersson, Senior ICU Consultant, Karolinska University Hospital
ClinicalTrials.gov Identifier:
NCT04203784
Other Study ID Numbers:
  • K 2019-9604
First Posted:
Dec 18, 2019
Last Update Posted:
Dec 19, 2019
Last Verified:
Dec 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:
Hemolysis

Study Results

No Results Posted as of Dec 19, 2019